Latest Articles
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More - Targeted Oncology
The Targeted Pulse: Endometrial Cancer Scores Multiple FDA Approvals, T-DXd Shows Promise in Breast Cancer, and More Targeted Oncology
Published: June 23, 2024, 7 a.m.
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer - OncLive
Lenvatinib/Pembrolizumab Misses OS End Points, But Still Shows Activity, in Advanced Endometrial Cancer OncLive
Published: June 21, 2024, 7 a.m.
ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma - OncLive
ROCSAN Study Step I Misses 16-Week ORR End Point in Endometrial or Ovarian Carcinosarcoma OncLive
Published: June 20, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive
Published: June 17, 2024, 7 a.m.
Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets - The ASCO Post
Study Misses Endpoints but Still Shows Benefit for Lenvatinib/Pembrolizumab in Endometrial Cancer Subsets The ASCO Post
Published: June 10, 2024, 7 a.m.
What endometriosis and polycystic ovary syndrome feel like, and how to support the women in your life who may be suffering - Missing Perspectives
What endometriosis and polycystic ovary syndrome feel like, and how to support the women in your life who may be suffering Missing Perspectives
Published: June 6, 2024, 7 a.m.
Employee left ‘bedridden’ by endometriosis wins unfair dismissal claim following “unilateral withdrawal” of work from home agreement - The HR Director Magazine
Employee left ‘bedridden’ by endometriosis wins unfair dismissal claim following “unilateral withdrawal” of work from home agreement The HR Director Magazine
Published: May 30, 2024, 7 a.m.
NLRC5 promotes endometrial carcinoma progression by regulating NF-κB pathway-mediated mismatch repair gene deficiency - Nature.com
NLRC5 promotes endometrial carcinoma progression by regulating NF-κB pathway-mediated mismatch repair gene deficiency Nature.com
Published: May 30, 2024, 7 a.m.
Bedbound estate agent awarded more than £31k for unfair dismissal - Property Industry Eye
Bedbound estate agent awarded more than £31k for unfair dismissal Property Industry Eye
Published: May 24, 2024, 7 a.m.
Identification of Biomarkers for Endometrial Cancer Shows Promise for Faster and Less Invasive Diagnosis - The University of Arizona College of Medicine – Phoenix
Identification of Biomarkers for Endometrial Cancer Shows Promise for Faster and Less Invasive Diagnosis The University of Arizona College of Medicine – Phoenix
Published: May 22, 2024, 7 a.m.
Link copied to clipboard!